Lupin receives approval for Rufinamide Oral Suspension

Lupin Limited (NSE: Lupin), global pharmaceutical company, announced today that it has received approval for its Rufinamide Oral Suspension, 40 mg/ml, from the United States Food and Drug Administration, to market a generic equivalent of Banzel® Oral Suspension, 40 mg/ml, of Eisai Inc.

Rufinamide Oral Suspension, 40 mg/ml is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Rufinamide Oral Suspension, 40 mg/ ml (RLD: Banzel®) had estimated annual sales of USD 124.5 million in the U.S. (IQVIA MAT September 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.930.3 as compared to the previous close of Rs. 972.2. The total number of shares traded during the day was 497042 in over 18602 trades.

The stock hit an intraday high of Rs. 991.8 and intraday low of 875. The net turnover during the day was Rs. 473712388.

Source : Equity Bulls

Keywords